← Ekachai Medical Care overview

Ekachai Medical Care vs Tenet Healthcare: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ekachai Medical Care Public Company Limited (EKH.BK)

Q3 2026
▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

  • Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.

    This is the key earnings result that shows EKH's core business is growing strongly.

  • New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.

    These new projects are the main growth drivers that will add revenue from Q3 2026 onward.

  • Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.

    This shows the positive trend continuing into Q3, confirming the growth story.

  • Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.

    Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

September 2026
▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

  • Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.

    This is the key earnings result that shows EKH's core business is growing strongly.

  • New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.

    These new projects are the main growth drivers that will add revenue from Q3 2026 onward.

  • Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.

    This shows the positive trend continuing into Q3, confirming the growth story.

  • Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.

    Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

Latest
▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

  • Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.

    This is the key earnings result that shows EKH's core business is growing strongly.

  • New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.

    These new projects are the main growth drivers that will add revenue from Q3 2026 onward.

  • Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.

    This shows the positive trend continuing into Q3, confirming the growth story.

  • Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.

    Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

Tenet Healthcare Corporation (THC)

Q3 2026
▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

  • USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.

    USPI is the main growth engine and directly explains the raised guidance and positive price impact.

  • Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.

    This is the core new financial event that directly moved the stock and improved future expectations.

  • Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.

    The expanded buyback is a new capital return action that boosts per-share value and investor confidence.

  • AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.

    This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

August 2026
▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

  • USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.

    USPI is the main growth engine and directly explains the raised guidance and positive price impact.

  • Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.

    This is the core new financial event that directly moved the stock and improved future expectations.

  • Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.

    The expanded buyback is a new capital return action that boosts per-share value and investor confidence.

  • AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.

    This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

Latest
▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

  • USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.

    USPI is the main growth engine and directly explains the raised guidance and positive price impact.

  • Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.

    This is the core new financial event that directly moved the stock and improved future expectations.

  • Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.

    The expanded buyback is a new capital return action that boosts per-share value and investor confidence.

  • AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.

    This is a new analyst view on a long-term profit driver that supports the bullish case for THC.